1) A
phase II study with the anti-CTLA-4 mAb Tremelimumab in
chemotherapy-resistant advanced malignant mesothelioma (MM): safety,
tolerability, clinical and immunologic activity (EUDRACT-2008-005171-95)
Luana Calabṛ, Anna Maria Di Giacomo, Aldo Morra, Ornella Cutaia,
Riccardo Danielli, Ester Fonsatti, Maresa Altomonte, Ramy Ibrahim,
Alessandra Di Pietro, Shengyan Hong, Luciano Mutti, Michele Maio
2) Long
term survival and immunological correlates in metastatic melanoma
treated with ipilimumab at 10 mgs within an expanded access program
A.M. Di Giacomo, L. Calabṛ, Danielli I. Pesce E. Fonsatti E. Bertocci
D. Giannarelli M. Biagioli M. Altomonte M. Maio ESMO 2012 |